53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications

Immunopathogenesis & Diagnostic Autoantibody Profiling in T1D

Type 1 diabetes mellitus (T1D) is a chronic autoimmune disorder characterized by targeted immune-mediated destruction of insulin-producing beta cells in the islets of Langerhans within the pancreas. This culminates in absolute insulin deficiency, obligating lifelong exogenous insulin replacement to sustain cellular metabolism and prevent fatal ketoacidosis.

Cellular & Genetic Pathogenesis

• T-Cell-Mediated Insulitis: Autoreactive CD4+ T-helper 1 (Th1) cells and CD8+ cytotoxic T lymphocytes infiltrate the pancreatic islets, releasing proinflammatory cytokines (interferon-gamma, tumor necrosis factor-alpha, interleukin-1-beta) and inducing perforin/granzyme- and Fas/FasL-mediated apoptosis of beta cells. Pancreatic alpha (glucagon-secreting) and delta (somatostatin-secreting) cells are characteristically spared.
• Genetic Susceptibility: Strongest association resides within the Human Leukocyte Antigen (HLA) class II locus on chromosome 6p21, specifically the HLA-DR3-DQ2 (DRB10301-DQB10201) and HLA-DR4-DQ8 (DRB10401-DQB10302) haplotypes. Individuals heterozygous for both DR3-DQ2 and DR4-DQ8 carry the highest genetic risk (~20-fold increased susceptibility).

The Islet Autoantibody Panel

While circulating autoantibodies do not directly mediate beta-cell destruction, they serve as critical, highly specific serological biomarkers of autoimmune insulitis:

                  SEROLOGICAL AUTOANTIBODY PROFILES IN TYPE 1 DIABETES

   Autoantibody Target        Abbreviation   Clinical Sensitivity & Diagnostic Utility
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Glutamic Acid              anti-GAD65     • Present in 70-80% of newly diagnosed patients.
   Decarboxylase 65                          • Most persistent autoantibody; remains detectable for years/decades.
                                             • Gold-standard serological marker for LADA in adults.

   Islet Antigen-2            anti-IA-2      • Present in 50-70% of pediatric and adolescent onsets.
   (Tyrosine Phosphatase)     (ICA512)       • Correlates strongly with rapid, aggressive beta-cell destruction.

   Zinc Transporter 8         anti-ZnT8      • Highly specific to the insulin secretory granule membrane.
                                             • Present in 60-70% of new onsets; fills diagnostic gaps when GAD65 is negative.

   Islet Cell Cytoplasmic     ICA            • Immunofluorescence assay detecting intracellular cytoplasmic antigens.
   Antibodies                                • Historical standard; widely replaced by recombinant GAD/IA-2/ZnT8 assays.

   Insulin Autoantibodies     IAA            • Most prevalent initial autoantibody in infants and young children (<5 years).
                                             • In adults, sensitivity is low (<20-30%).
                                             • Must be drawn before or within 1 to 2 weeks of exogenous insulin therapy!
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

The Three Staged Progression of Type 1 Diabetes

1. Stage 1 (Presymptomatic Autoimmunity): Presence of >=2 islet autoantibodies; normoglycemia (normal FPG, OGTT, and HbA1c); asymptomatic. Lifetime progression to clinical diabetes approaches 100%.
2. Stage 2 (Presymptomatic Dysglycemia): Presence of >=2 islet autoantibodies with emerging dysglycemia (FPG 100-125 mg/dL, 2-h OGTT 140-199 mg/dL, or HbA1c 5.7%-6.4%); asymptomatic. (Note: In 2022, the FDA approved Teplizumab, an anti-CD3 monoclonal antibody, administered as a 14-day IV infusion to delay the onset of Stage 3 clinical diabetes by a median of 2 to 3 years in Stage 2 patients aged >=8 years).
3. Stage 3 (Overt Clinical Disease): Autoantibodies present with symptomatic hyperglycemia fulfilling standard diagnostic criteria (polyuria, polydipsia, weight loss, or diabetic ketoacidosis).

Latent Autoimmune Diabetes in Adults (LADA: 'Type 1.5')

LADA represents a slowly progressive subtype of autoimmune diabetes presenting in adulthood. Diagnostic criteria include:

1. Age of onset >=30 to 35 years.
2. Presence of circulating islet autoantibodies (predominantly anti-GAD65 in >90% of cases).
3. Lack of requirement for exogenous insulin for at least the first 6 months following diagnosis.

• Clinical Trap: Patients with LADA are routinely misdiagnosed with type 2 diabetes due to their older age at onset. However, they typically possess a normal or lean BMI (<25 kg/m2), lack phenotypic features of metabolic syndrome (no severe hypertension, hypertriglyceridemia, or acanthosis nigricans), and experience rapid secondary failure of oral antidiabetic agents (sulfonylureas, metformin) within 12 to 24 months. Laboratory testing confirms a low or declining fasting C-peptide (<0.6 ng/mL or <0.2 nmol/L). Sulfonylureas must be avoided because they accelerate beta-cell exhaustion; early introduction of basal-bolus insulin preserves residual endogenous C-peptide and prevents ketoacidosis.

---

Intensive Basal-Bolus Insulin Therapy Architecture

Intensive insulin therapy strives to emulate normal human pancreatic physiology: continuous, low-level basal insulin secretion to suppress hepatic gluconeogenesis and lipolysis around the clock, interspersed with rapid bursts of prandial insulin to match mealtime carbohydrate absorption.

Total Daily Dose (TDD) Estimation & Distribution

In a metabolically stable patient with newly diagnosed type 1 diabetes outside the 'honeymoon phase':

• Starting TDD Formula: 0.4 to 0.6 units/kg/day of total insulin.
  • During the transient 'honeymoon phase' (temporary recovery of residual beta-cell secretion occurring weeks to months after diagnosis), requirements may fall to 0.2 to 0.4 units/kg/day.
  • During acute illness, systemic corticosteroid therapy, or adolescent pubertal growth spurts, requirements often rise to 0.8 to 1.2+ units/kg/day.
• The 50/50 Rule:
  • 50% of TDD administered as Basal Insulin (once or twice daily).
  • 50% of TDD administered as Prandial Bolus Insulin, divided across three meals (approximately 15% to 20% of TDD per meal).

                  STARTING TDD ESTIMATION (EXAMPLE: 70-KG ADULT)

   Parameter                        Calculation & Clinical Dose Allocation
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Estimated Total Daily Dose (TDD) 70 kg x 0.5 units/kg/day = 35 units total / day
   
   Basal Component (50% of TDD)     35 units x 0.50 = 17.5 units ──► 18 units Basal (e.g., Degludec)
   
   Prandial Component (50% of TDD)  35 units x 0.50 = 17.5 units ──► 17 units Prandial (divided over 3 meals)
                                    • Breakfast: 6 units rapid-acting analog (e.g., Lispro)
                                    • Lunch:     5 units rapid-acting analog
                                    • Dinner:    6 units rapid-acting analog
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Basal Insulin Formulations Comparison

                  PHARMACOKINETICS OF BASAL INSULIN FORMULATIONS

   Formulation        Trade Name      Onset       Peak        Duration     Biochemical Mechanism & Pearls
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════
   Degludec           Tresiba         30-90 min   None        > 42 hours   • Forms soluble multi-hexamers in SC depot.
   (U-100, U-200)                                 (Flat)                   • Half-life ~25 hr; ultra-flat profile.
                                                                           • Lowest rate of nocturnal hypoglycemia.
                                                                           • Flexible dosing time (>= 8 hr apart).

   Glargine U-300     Toujeo          6 hours     None        36 hours     • Forms a compact, dense subcutaneous depot.
                                                  (Flat)                   • Slower release and flatter curve than U-100.

   Glargine U-100     Lantus,         1-2 hours   None        20-24 hours  • Formulated at pH 4.0; micro-precipitates
                      Basaglar,                   (Flat)                     at physiological tissue pH 7.4.
                      Semglee                                              • DO NOT MIX in same syringe with other insulins!

   Detemir            Levemir         1-2 hours   Minimal     14-20 hours  • Binds interstitial and serum albumin via
                                                  (6-8 hr)                   myristic acid fatty acid side chain.
                                                                           • Frequently requires twice-daily (BID) dosing.

   NPH (Neutral       Humulin N,      1-3 hours   4-10 hours  12-18 hours  • Protamine crystalline suspension.
   Protamine Hagedorn) Novolin N                                           • Marked nocturnal hypoglycemia risk if given
                                                                             at dinner; MUST dose at bedtime (21:00-22:00).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════════

Prandial Insulin Formulations Comparison

• Rapid-Acting Analogs (Lispro [Humalog], Aspart [Novolog], Glulisine [Apidra]):
  • Onset: 10 to 15 minutes; Peak: 1 to 2 hours; Duration: 3 to 5 hours.
  • Amino acid substitutions prevent insulin hexamers from associating, allowing immediate monomeric dissociation and capillary absorption.
  • Administered 0 to 15 minutes before meals (or immediately after meals in toddlers or patients with unpredictable food intake).
• Ultra-Rapid Analogs (Faster Aspart [Fiasp], Faster Lispro [Lyumjev]):
  • Onset: 2 to 5 minutes; Peak: 45 to 60 minutes; Duration: 3 to 4 hours.
  • Formulated with excipients (niacinamide or treprostinil/citrate) that accelerate microvascular permeability and local absorption.
• Inhaled Human Insulin (Afrezza):
  • Dry powder formulation inhaled at mealtime. Peak action within 12 minutes; duration 1.5 to 3 hours.
  • Requires baseline spirometry (FEV1); strictly contraindicated in asthma, COPD, and active smokers due to acute bronchospasm risk.
• Regular (Crystalline) Human Insulin (Humulin R, Novolin R):
  • Onset: 30 to 60 minutes; Peak: 2 to 4 hours; Duration: 6 to 8 hours.
  • Must be injected 30 to 45 minutes prior to meal ingestion. Mismatches physiological carbohydrate absorption curves, predisposing to early postprandial hyperglycemia followed by late postprandial (3-5 hours) hypoglycemia.

---

Precision Advanced Dosing Formulas: The Rules of 500 and 1800

Optimal postprandial glycemic control in type 1 diabetes requires dynamic mealtime dosing that accounts for both dietary carbohydrate intake and pre-meal glycemic excursions.

1. Insulin-to-Carbohydrate Ratio (ICR: The Rule of 500)

The ICR defines how many grams of carbohydrate are metabolized by 1 unit of rapid-acting insulin:

$\text{ICR} = \frac{500}{\text{TDD}} \quad (\text{grams of carbohydrate per 1 unit of insulin})$

$\text{Carbohydrate Coverage Dose (units)} = \frac{\text{Total Grams of Carbohydrate in Meal}}{\text{ICR}}$

2. Insulin Sensitivity Factor / Correction Factor (ISF: The Rule of 1800)

The ISF defines the anticipated drop in blood glucose (in mg/dL) achieved by 1 unit of rapid-acting insulin:

$\text{ISF} = \frac{1800}{\text{TDD}} \quad (\text{mg/dL reduction in blood glucose per 1 unit of insulin})$

$\text{Correction Dose (units)} = \frac{\text{Current Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}}$

3. Total Mealtime Prandial Bolus Equation

$\text{Total Prandial Bolus} = \text{Carbohydrate Coverage Dose} + \text{Correction Dose}$

$\text{Total Prandial Bolus} = \left( \frac{\text{Meal Carbohydrates (g)}}{\text{ICR}} \right) + \left( \frac{\text{Current Glucose} - \text{Target Glucose}}{\text{ISF}} \right)$

[!TIP] CLINICAL PEARL: INSULIN ON BOARD (IOB) Rapid-acting insulin analogs possess an active duration of 3 to 4 hours. If a patient administers a correction bolus for hyperglycemia and checks their blood glucose 1 to 2 hours later, considerable unabsorbed insulin remains active in subcutaneous tissue (Insulin on Board). Administering another correction bolus before 3 to 4 hours have elapsed causes 'insulin stacking', the leading cause of severe postprandial hypoglycemia in intensive insulin therapy.

---

Continuous Glucose Monitoring (CGM) & Automated Insulin Delivery

Continuous Glucose Monitoring (CGM) utilizes subcutaneous transcutaneous enzymatic sensors (measuring interstitial glucose every 1 to 5 minutes) and has revolutionized outpatient glycemic surveillance, superseding intermittent capillary fingerstick blood glucose monitoring.

                  STANDARDIZED CGM AMBULATORY GLUCOSE PROFILE (AGP) TARGETS
                 (Consensus targets for non-pregnant adults with T1D / T2D)

   CGM Metric                     Target Range       Target Percentage    Clinical Significance
   ═════════════════════════════════════════════════════════════════════════════════════════════════════
   Time in Range (TIR)            70 to 180 mg/dL    > 70% of readings    • Each 10% increase in TIR reduces
                                  (3.9-10.0 mmol/L)  (> 16 hr 48 min/day)   retinopathy & microalbuminuria risk by ~40%.

   Time Below Range (TBR Level 1) 54 to 69 mg/dL     < 4% of readings     • Alert zone for hypoglycemia avoidance.
                                  (3.0-3.8 mmol/L)   (< 1 hour/day)

   Time Below Range (TBR Level 2) < 54 mg/dL         < 1% of readings     • Clinically significant, dangerous hypoglycemia
   (Severe Hypoglycemia)          (< 3.0 mmol/L)     (< 15 minutes/day)     mandating immediate regimen de-escalation.

   Time Above Range (TAR Level 1) 181 to 250 mg/dL   < 25% of readings    • Identifies postprandial excursions.
                                  (10.1-13.9 mmol/L) (< 6 hours/day)

   Time Above Range (TAR Level 2) > 250 mg/dL        < 5% of readings     • Severe hyperglycemia; ketone check trigger.
                                  (> 13.9 mmol/L)    (< 1 hr 12 min/day)

   Glycemic Variability (%CV)     %CV = (SD / Mean)  <= 36%               • Target <= 36% defines stable control;
                                  x 100                                     %CV > 36% reflects erratic glycemic excursions.

   Glucose Management             Calculated from    Matches HbA1c        • Mathematical estimation of laboratory HbA1c
   Indicator (GMI)                mean sensor glucose                     derived from >= 14 days of CGM sensor data.
   ═════════════════════════════════════════════════════════════════════════════════════════════════════

Automated Insulin Delivery (AID) Systems ('Artificial Pancreas')

AID systems combine a continuous subcutaneous insulin infusion (CSII) pump, a real-time CGM sensor, and an advanced algorithmic control loop (proportional-integral-derivative or model predictive control):

• Predictive Low-Glucose Suspend (PLGS): Algorithmic prediction of hypoglycemia 30 minutes in advance automatically attenuates or suspends basal insulin delivery, virtually eliminating nocturnal severe hypoglycemia.
• Automated Basal & Micro-Bolus Delivery: Algorithmic increases in basal rates and automated micro-boluses counteract rising glucose levels.
• Hybrid Closed-Loop: The user must still announce meals and manually input carbohydrate grams to deliver prandial boluses; basal adjustments and correction boluses are automated.

---

Unraveling Morning Hyperglycemia: Dawn Phenomenon vs. Somogyi Effect

A classic clinical conundrum is the patient with type 1 diabetes who awakens with marked fasting morning hyperglycemia (e.g., 220 to 280 mg/dL). Two diametrically opposed pathophysiological mechanisms produce this presentation:

                  DAWN PHENOMENON VS. SOMOGYI EFFECT DIFFERENTIATION

   Feature                  Dawn Phenomenon                       Somogyi Effect (Rebound Hyperglycemia)
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════
   Primary Mechanism        Circadian nocturnal surge of          Rebound hyperglycemia triggered by unrecognized
                            counter-regulatory hormones (GH,      nocturnal hypoglycemia; acute surge of epinephrine,
                            cortisol, glucagon, epinephrine)      glucagon, and cortisol drives intense hepatic
                            between 04:00 and 08:00 AM.           glycogenolysis and gluconeogenesis.

   03:00 AM Blood Glucose   ELEVATED or NORMAL                    LOW / HYPOGLYCEMIC
   (Key Diagnostic Pivot!)  (>= 100 to 140 mg/dL)                 (< 70 mg/dL, often 40-60 mg/dL)

   Nocturnal Symptoms       None; patient sleeps soundly          Nightmares, nocturnal diaphoresis, night sweats,
                                                                  waking with headache or tachycardia.

   Definitive Management    INCREASE bedtime basal insulin dose,  DECREASE evening or bedtime basal insulin dose,
                            switch to ultra-long-acting analog,   or provide a bedtime snack combining complex
                            or increase 04:00-08:00 pump rate.    carbohydrates and protein (peanut butter/cheese).
   ═════════════════════════════════════════════════════════════════════════════════════════════════════════

[!CAUTION] THE BOARD TRAP: NEVER ADJUST MORNING DOSES FOR MORNING NUMBERS When faced with morning fasting hyperglycemia, the catastrophic error is empirically increasing the bedtime basal insulin without checking the 03:00 AM blood glucose. If the patient has the Somogyi effect, increasing bedtime insulin deepens the 03:00 AM nocturnal hypoglycemia, which can induce fatal nocturnal hypoglycemic seizures or severe cardiac arrhythmias ('dead-in-bed syndrome'). Always obtain 03:00 AM readings before changing evening regimens.

---

Outpatient DKA Prevention & Sick-Day Management Protocol

Diabetic Ketoacidosis (DKA) is a life-threatening acute metabolic emergency characterized by the biochemical triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia/ketonuria (beta-hydroxybutyrate >3.0 mmol/L), and high anion gap metabolic acidosis (arterial pH <7.30, serum bicarbonate <18 mEq/L, anion gap >12 mEq/L).

Outpatient Sick-Day Education Rules

Infections (gastroenteritis, influenza, pneumonia, UTI) induce an intense surge of counter-regulatory stress hormones (cortisol, epinephrine, glucagon), promoting severe insulin resistance and lipolysis. Patient sick-day rules include:

1. NEVER Stop Basal Insulin: The cardinal rule of type 1 diabetes. Even if the patient is nauseated, anorexic, or actively vomiting and consuming zero calories, basal insulin must NEVER be omitted. Basal insulin is required to shut off adipose lipolysis and hepatic ketogenesis, not just to handle food. Withholding insulin because 'I am not eating' is the primary trigger of hospital-admitted DKA.
2. Frequent Glucose Monitoring: Check capillary glucose (or monitor CGM) every 2 to 4 hours around the clock.
3. Urine or Blood Ketone Testing: Test ketones every 2 to 4 hours whenever blood glucose is >250 mg/dL, or regardless of glucose level if the patient experiences nausea, vomiting, or abdominal pain.
   • Blood beta-hydroxybutyrate meters are vastly superior to urine acetoacetate dipsticks (which can yield false-negative results in early DKA or false-positive results with dehydration).
   • Beta-hydroxybutyrate <0.6 mmol/L: Normal.
   • 0.6 to 1.5 mmol/L: Impending ketosis; requires supplemental insulin and hydration.

   • 1.5 to 3.0 mmol/L: High risk of DKA; contact physician immediately.

   • 3.0 mmol/L: Severe DKA; requires immediate emergency department transport.

4. Aggressive Hydration: Consume at least 8 to 12 ounces (240-350 mL) of fluid per hour. If glucose is >200 mg/dL, consume calorie-free fluids (water, broth). If glucose drops <200 mg/dL due to poor food intake, switch to carbohydrate-containing fluids (sports drinks, diluted fruit juice) to maintain glucose between 150-200 mg/dL so that scheduled and supplemental insulin can continue to be administered safely.
5. Supplemental Correction Boluses: Administer rapid-acting insulin every 2 to 4 hours using the ISF. If moderate-to-large ketones are present, increase the calculated correction bolus by 10% to 20% of the patient's Total Daily Dose (TDD).
6. Emergency Department Referral Red Flags:
   • Persistent vomiting for >4 to 6 hours with complete inability to retain oral fluids.
   • Large ketones that fail to improve after two consecutive supplemental insulin correction doses.
   • Development of rapid, deep breathing (Kussmaul respirations), acetone-scented breath, or severe abdominal pain.
   • Lethargy, confusion, or altered mental status.